Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent

Coronary Artery Disease

Volumn 13, Issue 3, 2002, Pages 183-188

  Klugherz, Bruce D ^a   Llanos, Gerard ^b   Lieuallen, Warren ^b   Kopia, Gregory A ^b   Papandreou, George ^b   Narayan, Pallassana ^b   Sasseen, Brett ^a   Adelman, Steven J ^c   Falotico, Robert ^b   Wilensky, Robert L ^a   Sobel, B E ^d   Maseri, A ^d   Yacoub, M ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d Hospital of the University of Pennsylvania ^*

Author keywords

Cell cycle; Percutaneous coronary intervention; Restenosis

Indexed keywords

POLYMER; RAPAMYCIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD SAMPLING; CELL CYCLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; ILIAC ARTERY; IMPLANTATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS; STENT; SUSTAINED DRUG RELEASE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; GRAFT OCCLUSION, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; MODELS, CARDIOVASCULAR; PROSPECTIVE STUDIES; RABBITS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036305358     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200205000-00008     Document Type: Article

References (17)

1. Stent placement to prevent restenosis after angioplasty in small coronary arteries
2. Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis
3. Marked inflammatory sequellae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries
4. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
5. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
6. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
7. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
8. Gene delivery from a DNA-controlled release stent in porcine coronary arteries
9. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model
10. Inhibition of neointima formation after experimental coronary artery stenting. A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost
11. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model
12. Rapamycin in transplantation: A review of the evidence
13. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study: The Rapamune US Study Group
14. Restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit
15. A comparison of four stent designs on arterial injury, cellular proliferation, neointima formation and arterial dimensions in an experimental porcine model
16. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
17. Sustained suppression of neointimal proliferation by sirolimus-eluting stents